DiQi Pharmaceutical was recognized by the Guangdong Provincial Department of Science and Technology in 2017 as the Guangdong Provincial Engineering Technology Research Center for Quality Consistency Evaluation of Generic Drugs (hereinafter referred to as the "Center"). Our center has overseas background in technical services and management experience, familiar with the cGMP standardized production management process in Europe and America, and has successfully applied for dozens of drug registrations in the United States. We have accumulated rich experience in preparing validation plans, designing and executing experimental plans, and summarizing validation reports. We have detailed processes, standards, and time requirements for each research and development link (prescription process development, non clinical and clinical trial plan design), technology transfer, batch amplification, validation, and clinical trials, achieving effective connection between each link and ensuring the high success rate of the consistency evaluation of generic drugs and research and development of generic drugs projects.

Our center selects products with high technological barriers and a large market for project development, and transfers them to pharmaceutical companies in need. At the same time, we also accept commissioned development projects from pharmaceutical companies. During the research and development process, we pay attention to intellectual property protection. We have provided multiple consistency evaluation technology development services for Guangzhou Pharmaceutical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory and other branches of the group, Harbin Pharmaceutical Group, Lizhu Group, Yiling Pharmaceutical, Boya Biotechnology Group Guizhou Tian'an Pharmaceutical, Guangdong Huanan Pharmaceutical, Guangdong Yishu Pharmaceutical and other well-known pharmaceutical companies both inside and outside the province. These products are mainly produced and sold by the commissioning units. Our center conducts further research and development of prescription processes for these products to achieve in vitro quality consistency and in vivo bioequivalence with reference preparations, making the products more competitive in the market.